Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/Tipiracil Plus Talazoparib in Advanced Cancers
NCT04511039Phase 1Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jun 2021
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in colorectal cancer (CRC) and gastroesophageal junction cancer, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Incidence of Adverse Events at 14 days and Maximum tolerated dose/ recommended phase II dose at 14 days. Started Jun 2021; status: recruiting.
02
Drugs
talazoparib
03
Conditions
colorectal cancer (CRC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04511039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511039.